Page 63 - Read Online

Raffetto et al. Vessel Plus 2021;5:36 https://dx.doi.org/10.20517/2574-1209.2021.16 Page 29 of 30

211. Pochetti G, Gavuzzo E, Campestre C, et al. Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric
sulfonamide phosphonates. J Med Chem 2006;49:923-31. DOI PubMed
212. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997;15:61-75. DOI
PubMed
213. Skiles JW, Gonnella NC, Jeng AY. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr
Med Chem 2001;8:425-74. DOI PubMed
214. Puerta DT, Lewis JA, Cohen SM. New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding
groups. J Am Chem Soc 2004;126:8388-9. DOI PubMed
215. Bernardo MM, Brown S, Li ZH, Fridman R, Mobashery S. Design, synthesis, and characterization of potent, slow-binding inhibitors
that are selective for gelatinases. J Biol Chem 2002;277:11201-7. DOI PubMed
216. Johnson AR, Pavlovsky AG, Ortwine DF, et al. Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that
reduces cartilage damage in vivo without joint fibroplasia side effects. J Biol Chem 2007;282:27781-91. DOI PubMed
217. Chetty C, Bhoopathi P, Joseph P, Chittivelu S, Rao JS, Lakka S. Adenovirus-mediated small interfering RNA against matrix
metalloproteinase-2 suppresses tumor growth and lung metastasis in mice. Mol Cancer Ther 2006;5:2289-99. DOI PubMed
218. Dorecka M, Francuz T, Garczorz W, Siemianowicz K, Romaniuk W. The influence of elastin degradation products, glucose and
atorvastatin on metalloproteinase-1, -2, -9 and tissue inhibitor of metalloproteinases-1, -2, -3 expression in human retinal pigment
epithelial cells. Acta Biochim Pol 2014;61:265-70. PubMed
219. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and
macrophages. Arterioscler Thromb Vasc Biol 2003;23:769-75. DOI PubMed
220. Ichihara S, Noda A, Nagata K, et al. Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase
activity in a rat model of heart failure. Cardiovasc Res 2006;69:726-35. DOI PubMed
221. Chen Q, Jin M, Yang F, Zhu J, Xiao Q, Zhang L. Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular
formation and remodeling. Mediators Inflamm 2013;2013:928315. DOI PubMed PMC
222. Serra R, Gallelli L, Buffone G, et al. Doxycycline speeds up healing of chronic venous ulcers. Int Wound J 2015;12:179-84. DOI
PubMed
223. Renkiewicz R, Qiu L, Lesch C, et al. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side
effects in rats. Arthritis Rheum 2003;48:1742-9. DOI PubMed
224. Chiarelli N, Carini G, Zoppi N, Ritelli M, Colombi M. Transcriptome analysis of skin fibroblasts with dominant negative COL3A1
mutations provides molecular insights into the etiopathology of vascular Ehlers-Danlos syndrome. PLoS One 2018;13:e0191220.
DOI PubMed PMC
225. Greenberg BR, Golde DW. Erythropoiesis in familial erythrocytosis. N Engl J Med 1977;296:1080-4. DOI PubMed
226. Ang SO, Chen H, Hirota K, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet
2002;32:614-21. DOI PubMed
227. Gordeuk VR, Sergueeva AI, Miasnikova GY, et al. Congenital disorder of oxygen sensing: association of the homozygous Chuvash
polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood 2004;103:3924-32. DOI PubMed
228. Banka S, Chervinsky E, Newman WG, et al. Further delineation of the phenotype of severe congenital neutropenia type 4 due to
mutations in G6PC3. Eur J Hum Genet 2011;19:18-22. DOI PubMed PMC
229. Yin H, Zhang X, Wang J, et al. Downregulation of desmuslin in primary vein incompetence. J Vasc Surg 2006;43:372-8. DOI
PubMed
230. Urbanek T, Skop B, Wiaderkiewicz R, et al. Smooth muscle cell apoptosis in primary varicose veins. Eur J Vasc Endovasc Surg
2004;28:600-11. DOI PubMed
231. Le Flem L, Mennen L, Aubry ML, et al. Thrombomodulin promoter mutations, venous thrombosis, and varicose veins. Arterioscler
Thromb Vasc Biol 2001;21:445-51. DOI PubMed
232. Wang Q, Timur AA, Szafranski P, et al. Identification and molecular characterization of de novo translocation t(8;14)(q22.3;q13)
associated with a vascular and tissue overgrowth syndrome. Cytogenet Cell Genet 2001;95:183-8. DOI PubMed PMC
233. Tian XL, Kadaba R, You SA, et al. Identification of an angiogenic factor that when mutated causes susceptibility to Klippel-
Trenaunay syndrome. Nature 2004;427:640-5. DOI PubMed PMC
234. Fang J, Dagenais SL, Erickson RP, et al. Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for
the hereditary lymphedema-distichiasis syndrome. Am J Hum Genet 2000;67:1382-8. DOI PubMed PMC
235. Brice G, Mansour S, Bell R, et al. Analysis of the phenotypic abnormalities in lymphoedema-distichiasis syndrome in 74 patients
with FOXC2 mutations or linkage to 16q24. J Med Genet 2002;39:478-83. DOI PubMed PMC
236. Mellor RH, Brice G, Stanton AW, et al. Mutations in FOXC2 are strongly associated with primary valve failure in veins of the lower
limb. Circulation 2007;115:1912-20. DOI PubMed
237. Scappaticci S, Capra E, Cortinovis M, et al. Cytogenetic studies in venous tissue from patients with varicose veins. Cancer Genet
Cytogenet 1994;75:26-30. DOI PubMed
238. Sam RC, Burns PJ, Hobbs SD, et al. The prevalence of hyperhomocysteinemia, methylene tetrahydrofolate reductase C677T
mutation, and vitamin B12 and folate deficiency in patients with chronic venous insufficiency. J Vasc Surg 2003;38:904-8. DOI
PubMed
239. Sverdlova AM, Bubnova NA, Baranovskaya SS, Vasina VI, Avitisjan AO, Schwartz EI. Prevalence of the methylenetetrahydrofolate
reductase (MTHFR) C677T mutation in patients with varicose veins of lower limbs. Mol Genet Metab 1998;63:35-6. DOI PubMed
240. Gemmati D, Federici F, Catozzi L, et al. DNA-array of gene variants in venous leg ulcers: detection of prognostic indicators. J Vasc